MedTrace Logo

Psilocybin in Adults With and Without Autism Spectrum Disorder

NCT05651126 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-07-28

No results posted yet for this study

Summary

This study will test the hypothesis that brain systems are differentially regulated by serotonin in individuals with and without Autism Spectrum Disorder.

Conditions

Interventions

DRUG

Psilocybin 5 mg

Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

DRUG

Psilocybin 2 mg

Partial Serotonin (5HT) 1A/2A Receptor Agonist Psilocybin

DRUG

Placebo

Inactive placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-12
Primary Completion
2024-08-23
Completion
2024-08-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05651126 on ClinicalTrials.gov